Original article
With the end of the maximum legally possible term of eight years, the ARMIN model project, the Saxony-Thuringia pharmaceutical initiative, was ended on June 30, 2022. This means that a promising and now even positively evaluated care approach, which promotes and interlinks interprofessional collaboration between doctors and pharmacists for the benefit of the patient population being cared for together, is on the brink of extinction. It is no wonder that the actors used the opportunity when the evaluation data was presented to put forward political demands in order to maintain the positive effects of ARMIN beyond the end of the project and possibly even further develop them, although in the opinion of the ARMIN- Project partners must first create the necessary legal basis.
05.06.2023
Report on questions regarding the need for further development of hospital planning on the basis of service groups
05.06.2023
Key points paper from the German Catholic Hospital Association. V. (kkvd)
05.06.2023
Report on the hospital landscape in Saxony-Anhalt
05.06.2023
There are many family doctor-centered care models, also known as family doctor programs or models, in which the family doctor acts as the first point of contact for all health issues. Mainly AOKen and BKKen, but also Barmer or BIG, for example, offer their insured persons the opportunity to take part in various, sometimes very different family doctor programs - although overall there are quite a few participants compared to the majority of those receiving regular care in accordance with the care contract according to § 75 SGB V (1) are looked after. The HZV contract in Baden-Württemberg is the blueprint for family doctor-centered care (HZV) according to Section 73b SGB V (2), to which the contractual partners - the Baden-Württemberg Family Doctors Association, MEDI Baden-Württemberg and the AOK Baden-Württemberg - agree on one Press conference in Berlin was able to present scientific evaluation data over a period of ten years in a direct comparison of HZV and KV care for the first time.
05.06.2023
Why does a care innovation such as family doctor-centered care (HZV) according to Section 73b SGB V, a new world of care beyond standard KV care, work in Baden-Württemberg of all places? It's not that there aren't family doctor programs or models elsewhere in Germany, but firstly, not that long - currently at least 15 years - and secondly, not so consistently and, on top of that, constantly being developed. According to Johannes Bauernfeind, the CEO of AOK Baden-Württemberg, it is important that the HZV is not only more economical than the so-called standard care, but that more than 90 percent of the voluntarily enrolled patients are “very satisfied with this care offer as we have designed it have".
05.06.2023
Comment from Prof. Dr. rer. nat. Bernhard Müller, School of Physics and Astronomy, Monash University
05.06.2023
Knowledge from data – how it should and could be >> For a modern society with knowledge as one of its few raw materials, Germany has shown an astonishing degree of irrationality in dealing with the pandemic over the past three years – something that could hardly have been expected. To put this into perspective, it's important to take a look at […]
05.06.2023
Comment from Prof. Dr. med. Wolfram J. Herrmann, Deputy Institute Director, Institute for General Medicine at the Charité – University Medicine Berlin
05.06.2023
Since 2011, pharmaceutical companies in Germany have been required to submit an AMNOG benefit dossier to the G-BA when entering the market or expanding the approval of a new drug. On the basis of the IQWiG benefit assessment, the G-BA carries out an assessment of the additional benefit of the drug and largely follows the assessment by IQWiG. In April 2020, a revised, currently valid dossier template for Module 4 came into force, which drastically increases the already large presentation effort for pharmaceutical companies. However, given the increased presentation effort, a significant proportion does not appear to be relevant to the conclusions for the additional benefit awarded by the G-BA. In an efficient AMNOG process, only evaluations with actual added value should be made mandatory in the future.